SciELO - Scientific Electronic Library Online

 
vol.57 número6Pruebas de contraste de conformidad en tasas de tuberculosis pulmonar en zonas fronterizas de EcuadorConfiabilidad interobservador de las medidas para evaluar la publicidad del tabaco en los puntos de venta en México índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Salud Pública de México

versión impresa ISSN 0036-3634

Resumen

PICHON-RIVIERE, Andrés et al. Cost-effectiveness of quadrivalent vaccine against human papilloma virus in Argentina based on a dynamic transmission model. Salud pública Méx [online]. 2015, vol.57, n.6, pp.504-513. ISSN 0036-3634.

Objective. To assess the cost-effectiveness of the quadrivalent vaccine against human papillomavirus (HPV) in Argentina from the health system perspective. Materials and methods. A dynamic transmission model was used to estimate the impact of the vaccine on the incidence of cervical cancer, warts, and other HPV related diseases; in quality adjusted life years (QALYs); and in healthcare costs. Results. Vaccination could reduce the risk of cervical cancer by 60% and by 67% the risk of genital warts. Compared to a non-vaccine scenario, the immunization strategy showed an incremental benefit of 0.00234 QALY per person at an incremental cost of US$2.36, resulting in an incremental cost-effectiveness ratio of US$1007.55 per QALY gained. Sensitivity analysis proved the robustness of these results. Conclusions. Immunization with the quadrivalent vaccine was a cost-effective intervention in Argentina, and it was far below the threshold of one gross domestic product per capita (US$15 009) per QALY gained.

Palabras llave : immunization programs; papillomavirus infections; cost-effectiveness evaluation.

        · resumen en Español     · texto en Español     · Español ( pdf )